Watch
OFFICIAL COMMITTEE VIDEO · 3:13:23Pick a point on the bar to jump thereTap the bar to jump3:13:23
Why this hearing
On the record: 14 bills are on the agenda. 5 witnesses.
The panel includes a sheriff, a veterinary-practitioner group leader, a University of North Carolina scientist and a former director of SAMHSA's Center for Substance Abuse Treatment.
Real oversight or theater?
Did this hearing get real answers, or was it mostly speeches?
NO RATINGS YET
What each witness said
The main points of each witness’s written statement.
Scott OultonPresident, INTR3PID Solutions LLC
- Recommends expanding DEA's GUARDS method so labs report more substances and improve the depth and quality of NFLIS data.
- Recommends faster regional data sharing through NFLIS and integrating wastewater surveillance into national drug monitoring.
“By expanding what laboratories report, GUARDS allows NFLIS to evolve from a retrospective reporting system into a more actionable data platform.”
Dr. K. Fred Gingrich II, DVMExecutive Director, American Association of Bovine Practitioners
- Asks Congress to swiftly pass the Combating Illicit Xylazine Act to address illicit use and preserve veterinary access.
- Warns that xylazine supply disruptions could increase risks to people and compromise animal welfare.
“We respectfully urge Congress to act swiftly to pass the Combating Illicit Xylazine Act.”
Dennis LemmaSheriff, Seminole County, Florida, and Former President of the Major County Sheriffs of America
- Asks Congress to close scheduling gaps for xylazine and nitazenes and require serial numbers for pill presses.
- Asks Congress to fund and reauthorize HIDTA and expand treatment, Medicaid coverage, and reentry support.
“when we address both the drivers of addiction and the evolving drug supply at the same time, we save lives.”
Dr. Yngvild Olsen, MD, MPHFormer Director of the Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, and National Advisor, Manatt H
- Argues Congress should favor policies that increase access to effective opioid use disorder treatment, which saves lives.
- Warns Medicaid changes could disrupt coverage and treatment access, increasing overdose risk for people with substance use disorders.
“increasing access will save lives, while reducing access will take us back and lead to terrible consequences for individuals, families, and communities across the country.”
- Recommends expanding DEA's GUARDS method so labs report more substances and improve the depth and quality of NFLIS data.
- Recommends faster regional data sharing through NFLIS and integrating wastewater surveillance into national drug monitoring.
“By expanding what laboratories report, GUARDS allows NFLIS to evolve from a retrospective reporting system into a more actionable data platform.”
- Asks Congress to swiftly pass the Combating Illicit Xylazine Act to address illicit use and preserve veterinary access.
- Warns that xylazine supply disruptions could increase risks to people and compromise animal welfare.
“We respectfully urge Congress to act swiftly to pass the Combating Illicit Xylazine Act.”
- Asks Congress to close scheduling gaps for xylazine and nitazenes and require serial numbers for pill presses.
- Asks Congress to fund and reauthorize HIDTA and expand treatment, Medicaid coverage, and reentry support.
“when we address both the drivers of addiction and the evolving drug supply at the same time, we save lives.”
- Argues Congress should favor policies that increase access to effective opioid use disorder treatment, which saves lives.
- Warns Medicaid changes could disrupt coverage and treatment access, increasing overdose risk for people with substance use disorders.
“increasing access will save lives, while reducing access will take us back and lead to terrible consequences for individuals, families, and communities across the country.”
Who asked what
We haven’t logged who asked questions at this hearing yet.
Question logs come from the committee’s official video.
The subcommittee
32 members · 18 Republicans, 14 Democrats
- H. Morgan GriffithR-VA-9 · CHAIR
- Diana HarshbargerR-TN-1 · VICE CHAIR
- Troy BaldersonR-OH-12
- Cliff BentzR-OR-2
- Gus M. BilirakisR-FL-12
- Kat CammackR-FL-3
- Buddy CarterR-GA-1
- Dan CrenshawR-TX-2
- Neal P. DunnR-FL-2
- Erin HouchinR-IN-9
- John JamesR-MI-10
- John JoyceR-PA-13
- Thomas H. Kean, Jr.R-NJ-7
- Nicholas A. LangworthyR-NY-23
- Mariannette Miller-MeeksR-IA-1
- Jay ObernolteR-CA-23
- Michael A. RulliR-OH-6
- Brett GuthrieR-KY-2 · EX OFFICIO
- Diana DeGetteD-CO-1 · RANKING
- Jake AuchinclossD-MA-4
- Nanette Diaz BarragánD-CA-44
- Troy A. CarterD-LA-2
- Debbie DingellD-MI-6
- Lizzie FletcherD-TX-7
- Robin L. KellyD-IL-2
- Greg LandsmanD-OH-1
- Alexandria Ocasio-CortezD-NY-14
- Raul RuizD-CA-25
- Kim SchrierD-WA-8
- Lori TrahanD-MA-3
- Marc A. VeaseyD-TX-33
- Frank Pallone, Jr.D-NJ-6 · EX OFFICIO
Witnesses
- Scott OultonPresident, INTR3PID Solutions LLCWITNESS TYPENon-governmentalTHIS CONGRESSFirst appearance
- Dr. K. Fred Gingrich II, DVMExecutive Director, American Association of Bovine PractitionersWITNESS TYPENon-governmentalTHIS CONGRESSFirst appearance
- Dennis LemmaSheriff, Seminole County, Florida, and Former President of the Major County Sheriffs of AmericaWITNESS TYPENon-governmentalTHIS CONGRESSFirst appearance
- Dr. Nabarun Dasgupta, PhD, MPHSenior Scientist and Gillings Innovation Fellow, University of North Carolina at Chapel HillWITNESS TYPENon-governmentalTHIS CONGRESSFirst appearance
- Dr. Yngvild Olsen, MD, MPHFormer Director of the Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, and National Advisor, Manatt HWITNESS TYPENon-governmentalTHIS CONGRESSFirst appearance
On the agenda
H.R. 1227Alternatives to PAIN ActSponsor: Mariannette Miller-Meeks R-IA-1 · Introduced Feb 12, 2025 · 114 cosponsors (51 R, 63 D)
114 COSPONSORS · 51 R · 63 D
- Introduced
- In committee▲ THIS HEARING
- Reported
- Passed House
- Passed Senate
- Law
In committee · Next step: a committee markup, scheduled for May 13.
H.R. 1266Combating Illicit Xylazine ActSponsor: Jimmy Panetta D-CA-19 · Introduced Feb 12, 2025 · 114 cosponsors (63 R, 51 D)
114 COSPONSORS · 63 R · 51 D
- Introduced
- In committee
- Reported
- Passed House
- Passed Senate
- Law
Passed House · Passed the House. Next step: the Senate.
H.R. 1561ALERT Communities ActSponsor: Jasmine Crockett D-TX-30 · Introduced Feb 25, 2025 · 1 cosponsor (1 R)
1 COSPONSOR · 1 R
- Introduced
- In committee
- Reported
- Passed House
- Passed Senate
- Law
Reported · Next step: a floor vote. None is scheduled.
H.R. 2004Tyler’s LawSponsor: Ted Lieu D-CA-36 · Introduced Mar 10, 2025 · 65 cosponsors (30 R, 35 D)
65 COSPONSORS · 30 R · 35 D
- Introduced
- In committee
- Reported
- Passed House
- Passed Senate
- Law
Passed House · Passed the House. Next step: the Senate.
In the news
No news coverage of this hearing yet.
Timeline & documents
- Hearing noticed (done)MAR 19
- Held (done)MAR 26 · 2:00 PM – 5:00 PM
- Video posted (done)MAR 26 · 5:00 PM
- Written testimony posted (done)MAR 24 · 2:40 PM
- Questions for the record (not yet)NOT POSTED YET
- Printed transcript (not yet)USUALLY ABOUT 5 MONTHS AFTER THE HEARING
- Meeting noticePDF (opens the committee’s file)
- Committee memoPDF (opens the committee’s file)
- Written testimony (5)PAGE (opens the committee’s file)
- Statements for the record (5)PAGE (opens the committee’s file)
- Questions for the recordPENDING
- Printed transcriptPENDING
- Bill text (14)PAGE (opens the committee’s file)
Written follow-up questions from members, answered after the hearing. aren’t posted yet. The printed transcript usually comes out about 5 months after the hearing (of hearings printed so far).
Related hearings
H · ENERGY & COMMERCE · MAY 13, 2026Votes on ten health care billsThe same bills were on its agendaH · ENERGY & COMMERCE · JUN 25, 2026Votes on 15 health care billsThe same bills were on its agendaH · ENERGY & COMMERCE · JUL 1, 2026Nine drug and electricity grid billsThe same bills were on its agenda